Announcement by the President of AOTMiT on the current threshold for the cost of obtaining an additional year of life adjusted for quality
Pursuant to Article 12(13) and Article 19(2)(7) of the Act of May 12, 2011, on the reimbursement of medicines, foodstuffs intended for particular nutritional uses, and medical devices (Journal of Laws of 2025, item 907, as amended), the threshold for the cost of obtaining an additional year of life adjusted for quality, and if it is not possible to determine this cost – the cost of obtaining an additional year of life, shall be set at three times the Gross Domestic Product per capita referred to in Article 6(1) of the Act of October 26, 2000, on the method of calculating the value of the annual gross domestic product (Journal of Laws of 2021, item 151).
Taking into account the above provisions and the latest announcement of the President of the Statistics Poland of October 30, 2025, on estimates of the gross domestic product per capita in 2021-2023, according to which the gross domestic product per capita in 2021 -2023 in Poland has been set at PLN 81,607, the threshold for the cost of obtaining an additional year of life adjusted for quality is PLN 244,821 (3 x PLN 81,607), until the next announcement of the President of the Central Statistical Office in this regard is made.
Thus, the amount of PLN 244,821 should be used in economic analyses as a reference point for estimating the cost of an additional year of life adjusted for quality resulting from the replacement of optional technologies, including reimbursed optional technologies, with the requested technology in accordance with § 5(2)(4) of the Regulation of the Minister of Health of October 24, 2023, on the minimum requirements to be met by analyses included in applications for reimbursement and determination of the net sale price, for reimbursement and determination of the net sale price of a drug technology of high clinical value and for an increase in the net sale price of a drug, foodstuff for special nutritional purposes, and medical device that have no reimbursed equivalent for a given indication (Journal of Laws of 2023, item 2345).